Long-term safety and effectiveness of evinacumab in people with homozygous familial hypercholesterolemia: a plain language summary [0.03%]
evinacumab治疗纯合子家族性高胆固醇血症长期安全性和有效性的简易摘要
Daniel Gaudet,Susanne Greber-Platzer,Laurens F Reeskamp et al.
Daniel Gaudet et al.
Ian Welch,Brian Case
Ian Welch
Danish Saleh,Maeve Eskandari,Lubna Choudhury
Danish Saleh
Aficamten is a novel cardiac myosin inhibitor that has completed a Phase III trial for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Aficamten was developed to optimize pharmacokinetic properties and clinical tolerability ...
Plain language summary: oral treprostinil (Orenitram) for the treatment of pulmonary arterial hypertension (PAH) [0.03%]
简明摘要：口服曲前列尼尔(Orenitram)治疗肺动脉高压(PAH)
Brittany N J Davis,Tara Suplicki,Natalie Patzlaff et al.
Brittany N J Davis et al.
Stenting strategy and imaging use in left main percutaneous coronary intervention: insights from a 15-year registry [0.03%]
左主干经皮冠状动脉介入治疗的支架植入策略及影像学应用：一项为期15年的注册研究见解
Judit Andreka,Fazila-Tun-Nesa Malik,Mariam Khandaker et al.
Judit Andreka et al.
Background: Left main (LM) percutaneous coronary intervention (PCI) remains a major interventional challenge, with outcomes influenced by various patient- and procedure-related factors. ...
Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists [0.03%]
美国心脏病专家和肾病学家对动脉粥样硬化性心血管疾病中高敏C反应蛋白检测的感知：一项调查研究
Lei Lv,Ty J Gluckman,Matthew Strum et al.
Lei Lv et al.
Introduction: High-sensitivity C-reactive protein (hsCRP) is a biomarker of systemic inflammation (SI) and its elevated level is considered a risk-enhancing factor for cardiovascular disease in primary prevention. This st...
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome [0.03%]
塞meglutide：心血管-肾脏-代谢综合征管理的关键药物
Richard J MacIsaac
Richard J MacIsaac
Recent trials underscore the cardiovascular (CV), renal, and metabolic benefits of semaglutide in individuals with and without type 2 diabetes (T2D). In T2D, semaglutide enhances glycemic control, reduces major adverse CV events (MACE), and...
Favorable cardiac remodeling in response to treatment in obstructive hypertrophic cardiomyopathy: a current appraisal [0.03%]
梗阻性肥厚型心肌病治疗反应良好心脏重塑的当前评估
Susan Keen,Milind Y Desai
Susan Keen
Hypertrophic cardiomyopathy is a heterogenous genetic condition caused by myocyte disarray with varying degrees of interstitial fibrosis. Traditional management strategies focused on symptom mitigation and sudden cardiac death prevention am...
Nikita Jhawar,Shahyar Michael Gharacholou
Nikita Jhawar
Coronary kinking represents an underrecognized diagnosis which typically arises as a complication of invasive cardiovascular procedures but may also be non-iatrogenic and nonatheromatous. Determining the etiology of coronary kinking poses a...
Evolution of the management of ultrarare inherited arrhythmias and cardiomyopathies [0.03%]
超罕见遗传性心律失常和心肌病的管理进展
Saif Dababneh,Thomas M Roston
Saif Dababneh